BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $97 from $86 and keeps a Buy rating on the shares after having hosted fireside chats with management teams at the firm’s CNS Therapeutics Conference.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Promising Growth Driven by Key Product Launches and Strategic Partnerships
- Ionis Pharmaceuticals gets Breakthrough Therapy designation for zilganersen
- Ionis Pharmaceuticals granted Breakthrough Therapy designation for olezarsen
- Arrowhead price target raised to $48 from $27 at Goldman Sachs
- Ionis Pharmaceuticals Completes $770M Convertible Notes Offering